By Fineline Cube TaiGen Biotechnology and Joincare Pharmaceutical Group (SHA: 600380) announced a licensing agreement for the collaborative development and commercialization of TG‑4318, a novel Dipeptidyl Peptidase 1 (DPP1) inhibitor for bronchiectasis, covering Greater China (Mainland China, Hong Kong, and Macau).
Deal Structure & Partnership Terms
| Item | Detail |
|---|---|
| Licensor | TaiGen Biotechnology (4157) |
| Licensee | Joincare Pharmaceutical Group (600380.SH) |
| Product | TG‑4318 (DPP1 inhibitor) |
| Indication | Bronchiectasis (primary) |
| Territory | Greater China – exclusive rights |
| Development Stage | Preclinical; preparing for clinical trials |
| Financial Terms | Upfront signing fee + development milestones + sales royalties |
| Responsibilities | Joincare leads clinical trials, manufacturing, and commercialization in Greater China; collaborates on global development |
| Strategic Context | Second innovative drug collaboration following TG‑1000 influenza antiviral partnership |
Drug Profile & Mechanism of Action
- Mechanism: DPP1 inhibitor with a novel mechanism of action targeting neutrophil‑mediated inflammation in bronchiectasis
- Innovation: Best‑in‑class potential due to selective DPP1 inhibition and favorable preclinical safety profile
- Clinical Progress: Currently in preclinical evaluation; IND‑enabling studies underway to support global clinical trial initiation
- Market Position: First‑in‑class DPP1 inhibitor approach for bronchiectasis in China, addressing high unmet need in rare respiratory disease
Market Impact & Commercial Outlook
- Bronchiectasis Burden: Estimated 1.5–2.0 million patients in Greater China suffer from bronchiectasis, with limited approved therapies beyond symptomatic management.
- Revenue Potential: Analysts forecast ¥500–700 million (US$70–100 million) peak annual sales in Greater China by 2030, assuming successful Phase III trials and NRDL inclusion.
- Strategic Synergy: Joincare’s 4,000‑person respiratory sales force and hospital network provide immediate commercial infrastructure; TaiGen retains upside via milestones and royalties.
- Global Ambition: Partnership includes joint global development, positioning TG‑4318 for potential ex‑China licensing opportunities in US/EU markets.
- Pipeline Validation: Second collaboration underscores successful track record between the companies, reducing execution risk for investors.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding development timelines, clinical outcomes, and revenue projections for TG‑4318. Actual results may differ materially due to regulatory risks, clinical trial outcomes, and competitive dynamics in the respiratory market.-Fineline Info & Tech